A Medicare pilot program aimed at expanding access to GLP-1 weight-loss medications has been delayed until at least 2027, according to an announcement made this week. Insurers raised concerns over the program’s costs and implementation, prompting the postponement.
The initiative, known as BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth), was developed by the Centers for Medicare & Medicaid Services (CMS) to explore broader Medicare coverage for GLP-1 drugs. These medications, initially approved for Type 2 diabetes, have seen a surge in demand due to their effectiveness as weight-loss treatments.
Insurers’ Concerns Stall Progress
Despite the program’s potential to improve health outcomes and reduce obesity-related healthcare costs, insurers have expressed reluctance to participate. Financial risks associated with covering high-priced GLP-1 medications, coupled with unresolved questions about long-term patient eligibility and program costs, have hindered progress.
"The promises that were made by the administration of drug coverage and the BALANCE pilot program will have to wait", said Kevin Thompson, CEO of 9i Capital Group and host of the 9innings podcast. "If beneficiaries want coverage it looks like out-of-pocket cost may not be capped and will be borne by the patient, not the insurer."
GLP-1 medications can cost thousands of dollars per year per patient, presenting a significant financial challenge for Medicare programs. Drew Powers, founder of Powers Financial Group, explained, "GLP-1s are already widely used by Medicare and Medicaid beneficiaries as a diabetes drug, and the costs associated already make up an outsized portion of each program’s budget. If use was expanded to also include weight loss, the costs could become astronomical."
Major players in the healthcare and pharmaceutical industries, including UnitedHealthcare, CVS, and Eli Lilly, declined to participate in the pilot before the April 20 enrollment deadline. Bobby Hunter, UnitedHealthcare’s CEO of government programs, elaborated during an earnings call, stating, "We’d like to find a path to ‘yes’ there on coverage over time, but there are some notable challenges and outstanding questions with the currently planned structure. We’re still working through that process internally."
Implications for Medicare Beneficiaries
The delay leaves many Medicare beneficiaries who might benefit from GLP-1 medications for weight loss facing significant out-of-pocket expenses. Currently, Medicare coverage for these drugs is limited to treating diabetes under existing rules, leaving those seeking coverage for weight loss without widespread support.
Any permanent changes to Medicare’s coverage of weight-loss drugs would require congressional action and new guidance from CMS. According to Powers, "It is difficult at this point for doctors and lawmakers to determine if the cost of the drug would be paid for over time by the decrease in obesity-related expenses."
Next Steps for GLP-1 Coverage
With no immediate solutions in sight, Medicare’s delayed pilot raises broader questions about the future of weight-loss drug coverage for older adults. For now, the potential of GLP-1 medications to reduce obesity-related conditions like diabetes and heart disease remains largely untapped within Medicare, leaving beneficiaries with limited options.
The BALANCE pilot program, once seen as a step toward addressing these issues, now faces an uncertain future as it awaits potential implementation in 2027 or beyond.
Recent Comments